Top Stories
The Eleven Therapeutics spinout is starting with kidney and vascular diseases, where it says known genetic targets have remained difficult to reach with existing medicines.
The biotech's lead asset targets striated muscle to treat facioscapulohumeral muscular dystrophy.
BNT113 failed to significantly extend progression-free survival (PFS) when added to Keytruda in a study of patients with metastatic HPV16-positive head and neck cancer.
Sales of Tremfya reached $2.4 billion, above analyst expectations of $2.2 billion, with no signs that the newly-launched oral psoriasis drug Icotyde is affecting the product's growth trajectory.
Enodia will screen, optimise and develop Sec61 inhibitor candidates while Pfizer will be responsible for all clinical, manufacturing, regulatory and commercial activities.
Conference News
SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of nov...
Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboiResults build on previously reported week 12 fin...
– Biomarker data demonstrate osteoclast activation at low doses of vantictumab without impacting osteoblast activity, strengthening therapeutic rationale for the treatment of autosomal dominant osteop...
CHICAGO--(BUSINESS WIRE)-- Syntax Bio will present new research on its Cellgorithm™ cell-programming platform at the International Society for Stem Cell Research (ISSCR) iPSC 20th Anniversary Symposiu...
– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity –– IND-enabling development underway to support Phase 1 clinical pr...
